Pantalone, Kevin M.
Rogen, Bruce
Zirm, Patty
Xiao, Huijun
Bena, James
Barnard, Gretchen
Borukh, Elena
Peechakara, Seenia
Griebeler, Marcio L.
Young, James B.
Burguera, Bartolome http://orcid.org/0000-0001-9808-8327
Clinical trials referenced in this document:
Documents that mention this clinical trial
An Obesity-Centric Approach with and Without Anti-Obesity Medications Compared to the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled Trial (EMPOWER-T2D)
https://doi.org/10.1007/s13300-024-01563-0
Article History
Received: 5 February 2024
Accepted: 4 March 2024
First Online: 4 April 2024
Declarations
:
: Kevin M. Pantalone has received personal fees from AstraZeneca, Bayer, Corcept Therapeutics, Diasome, Eli Lilly, Merck, Novo Nordisk, and Sanofi; and research support from Bayer, Merck, Novo Nordisk, and Twin Health. He is also an Editorial Board member of <i>Diabetes Therapy</i>, but was not involved in the selection of peer reviewers for the manuscript, nor any of the subsequent editorial decisions. Bartolome Burguera has received research support from Novo Nordisk. Bruce Rogen, Patty Zirm, Huijun Xiao, James Bena, Gretchen Barnard, Elena Borukh, Seenia Peechakara, Marcio L. Griebeler, and James B. Young have nothing to disclose.
: The study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice, the principles of the Declaration of Helsinki, and all applicable local ethical and legal requirements. The Cleveland Clinic institutional review board approved the study protocol (approval number IRB 20-648). All participants provided written informed consent.